An expert in medicinal chemistry and molecular drug-target interaction of G protein-coupled receptors, with particular emphasis on the β2-adrenergic receptors. Uses a combination of molecular modeling and experimental (in vitro) studies to develop substances with selective action on a specific subtype of a receptor and/or on a specific intracellular signaling event. The main achievements are development of a series of novel subtype and signal selective agonists of the β2-adrenergic receptor, one of them appeared as very effective dual action (β2-AR agonist and GPR55 antagonist) molecule that is a drug candidate for pancreatic cancer treatment and recent developments of selective peptide analogs that regulate GPR116 adhesion receptor. Another line of activity is medicinal chemistry of multi-target pharmacophores.

Professor Jóźwiak is a laureate of the UCB-Ehrlich Award for Excellence in Medicinal Chemistry (European Federation for Medicinal Chemistry – 2012 Edition).